Reata stock surges on positive data in CKD patients

Shares in Reata Pharmaceuticals nearly doubled by value in trading this week, surging higher on positive mid-stage data for the Texas-based biopharma's experimental drug bardoxolone methyl in patients with chronic kidney disease (CKD).